Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake. / Dalbøge, Louise S.; Pedersen, Søren L.; van Witteloostuijn, Søren Blok; Rasmussen, Jakob Ewald; Rigbolt, Kristoffer T. G.; Jensen, Knud Jørgen; Holst, Birgitte; Vrang, Niels; Jelsing, Jacob.
I: Journal of Peptide Science, Bind 21, Nr. 2, 2015, s. 85-94.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake
AU - Dalbøge, Louise S.
AU - Pedersen, Søren L.
AU - van Witteloostuijn, Søren Blok
AU - Rasmussen, Jakob Ewald
AU - Rigbolt, Kristoffer T. G.
AU - Jensen, Knud Jørgen
AU - Holst, Birgitte
AU - Vrang, Niels
AU - Jelsing, Jacob
PY - 2015
Y1 - 2015
N2 - Neuromedin U (NMU) is a 25 amino acid peptide expressed and secreted in the brain and gastrointestinal tract. Data have shown that peripheral administration of human NMU decreases food intake and body weight and improves glucose tolerance in mice, suggesting that NMU receptors constitute a possible anti-diabetic and anti-obesity drug target. However, the clinical use of native NMU is hampered by a poor pharmacokinetic profile. In the current study, we report in vitro and in vivo data from a series of novel lipidated NMU analogs. In vitro plasma stability studies of native NMU were performed to investigate the proteolytic stability and cleavage sites using LC-MS. Native NMU was found to be rapidly cleaved at the C-terminus between Arg24 and Asn25, followed by cleavage between Arg16 and Gly17. Lipidated NMU analogs were generated using solid-phase peptide synthesis, and in vitro potency was investigated using a human embryonic kidney 293-based inositol phosphate accumulation assay. All lipidated analogs had preserved in vitro activity on both NMU receptors with potency improving as the lipidation site was moved away from the receptor-interacting C-terminal octapeptide segment. In vivo efficacy was assessed in lean mice as reduction in food intake after acute subcutaneous administration of 1, 0.3, 0.1, and 0.03μmol/kg. These lipidated NMU analogs prolonged the anorectic effect of NMU in a dose-dependent manner. This was likely an effect of improved pharmacokinetic properties because of improved vitro plasma stability. Accordingly, the data demonstrate that lipidated NMU analogs may represent drug candidates for the treatment of obesity.
AB - Neuromedin U (NMU) is a 25 amino acid peptide expressed and secreted in the brain and gastrointestinal tract. Data have shown that peripheral administration of human NMU decreases food intake and body weight and improves glucose tolerance in mice, suggesting that NMU receptors constitute a possible anti-diabetic and anti-obesity drug target. However, the clinical use of native NMU is hampered by a poor pharmacokinetic profile. In the current study, we report in vitro and in vivo data from a series of novel lipidated NMU analogs. In vitro plasma stability studies of native NMU were performed to investigate the proteolytic stability and cleavage sites using LC-MS. Native NMU was found to be rapidly cleaved at the C-terminus between Arg24 and Asn25, followed by cleavage between Arg16 and Gly17. Lipidated NMU analogs were generated using solid-phase peptide synthesis, and in vitro potency was investigated using a human embryonic kidney 293-based inositol phosphate accumulation assay. All lipidated analogs had preserved in vitro activity on both NMU receptors with potency improving as the lipidation site was moved away from the receptor-interacting C-terminal octapeptide segment. In vivo efficacy was assessed in lean mice as reduction in food intake after acute subcutaneous administration of 1, 0.3, 0.1, and 0.03μmol/kg. These lipidated NMU analogs prolonged the anorectic effect of NMU in a dose-dependent manner. This was likely an effect of improved pharmacokinetic properties because of improved vitro plasma stability. Accordingly, the data demonstrate that lipidated NMU analogs may represent drug candidates for the treatment of obesity.
KW - Acylation
KW - Food intake
KW - Lipidation
KW - NMU
KW - NMU analogs
KW - Obesity
U2 - 10.1002/psc.2727
DO - 10.1002/psc.2727
M3 - Journal article
C2 - 25521062
VL - 21
SP - 85
EP - 94
JO - Journal of Peptide Science
JF - Journal of Peptide Science
SN - 1075-2617
IS - 2
ER -
ID: 135368382